{"id":415,"date":"2023-08-25T13:57:15","date_gmt":"2023-08-25T05:57:15","guid":{"rendered":"https:\/\/consulting-hmk.com\/?p=415"},"modified":"2024-01-18T09:56:47","modified_gmt":"2024-01-18T01:56:47","slug":"retagliptin-phosphate-tablets-approved-for-marketing-by-china-nmpa","status":"publish","type":"post","link":"https:\/\/www.consulting-hmk.com\/es\/retagliptin-phosphate-tablets-approved-for-marketing-by-china-nmpa\/","title":{"rendered":"Retagliptin Phosphate Tablets aprobado para su comercializaci\u00f3n por la NMPA de China"},"content":{"rendered":"<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u00a0 \u00a0 \u00a0 Recientemente, el f\u00e1rmaco innovador de categor\u00eda 1 Retagliptin Phosphate Tablets (nombre comercial chino: \u745e\u6cfd\u5510) de Jiangsu Hengrui Pharmaceuticals Co., Ltd. ha sido aprobado por la NMPA china. Est\u00e1 indicado para mejorar el control de la glucemia en pacientes adultos con diabetes de tipo 2.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><img decoding=\"async\" loading=\"lazy\" class=\"wp-image-395 aligncenter\" title=\"Retagliptin Phosphate Tablets aprobado para su comercializaci\u00f3n por la NMPA de China\" src=\"https:\/\/consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-300x168.jpg\" alt=\"Retagliptin Phosphate Tablets aprobado para su comercializaci\u00f3n por la NMPA de China\" width=\"568\" height=\"318\" srcset=\"https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-300x168.jpg 300w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-1024x574.jpg 1024w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-768x430.jpg 768w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-1536x861.jpg 1536w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/07\/vecteezy_beauty-treatment-items-for-spa-procedures-illustration-ai_23802276_19-2048x1148.jpg 2048w\" sizes=\"(max-width: 568px) 100vw, 568px\" \/><\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">El fosfato de retagliptina es un inhibidor de la dipeptidil peptidasa 4 (DPP-4) que inhibe la DPP-4 para hidrolizar la hormona incretina, aumentando as\u00ed la concentraci\u00f3n plasm\u00e1tica de p\u00e9ptido-1 similar al glucag\u00f3n (GLP-1) activo y de polip\u00e9ptido similar a la insulina dependiente de la glucosa (GIP). Aumenta la liberaci\u00f3n de insulina de forma dependiente de la glucosa y disminuye la de glucag\u00f3n para reducir la glucemia. La comercializaci\u00f3n de este medicamento ofrece nuevas opciones de tratamiento para los pacientes adultos con diabetes de tipo 2.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Recientemente, el f\u00e1rmaco innovador de categor\u00eda 1 Retagliptin Phosphate Tablets de Jiangsu Hengrui Pharmaceuticals Co., Ltd. ha sido aprobado por la NMPA de China. Est\u00e1 indicado para mejorar el control de la glucemia en pacientes adultos con diabetes de tipo 2.<\/p>","protected":false},"author":4,"featured_media":416,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[70],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.consulting-hmk.com\/es\/wp-json\/wp\/v2\/posts\/415"}],"collection":[{"href":"https:\/\/www.consulting-hmk.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.consulting-hmk.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/es\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/es\/wp-json\/wp\/v2\/comments?post=415"}],"version-history":[{"count":0,"href":"https:\/\/www.consulting-hmk.com\/es\/wp-json\/wp\/v2\/posts\/415\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/es\/wp-json\/wp\/v2\/media\/416"}],"wp:attachment":[{"href":"https:\/\/www.consulting-hmk.com\/es\/wp-json\/wp\/v2\/media?parent=415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/es\/wp-json\/wp\/v2\/categories?post=415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/es\/wp-json\/wp\/v2\/tags?post=415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}